|Day's Range||33.82 - 34.12|
|52 Week Range||25.55 - 35.04|
|PE Ratio (TTM)||25.38|
|Dividend & Yield||1.90 (5.60%)|
|1y Target Est||N/A|
AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a late-stage study, boosting hopes for a medicine that is expected to reach the market later this year. Benralizumab will compete with GlaxoSmithKline's Nucala and Teva's Cinqair - two other new antibody drugs for severe asthma - but AstraZeneca believes its product's potency and convenient dosing could give it an edge. While most investor focus is on AstraZeneca's cancer research, particularly the immunotherapy drug durvalumab , the company also has a long history in respiratory therapy that it plans to build on with benralizumab.
AstraZeneca, the Anglo-Swedish pharmaceuticals group, has sold the European commercial rights to its Seloken heart medicines in a deal worth more than $300m, as it moves to focus on new products in what ...